Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Burkitt Lymphoma 1

Interventions

Rituximab 16ibrutinib 9Bortezomib 8fludarabine phosphate 7Lenalidomide 6Cyclophosphamide 5Bendamustine Hydrochloride 5Peripheral Blood Stem Cell Transplantation 4Flow Cytometry 4Dasatinib 4tanespimycin 3pomalidomide 3belinostat 3Vorinostat 3Polymerase Chain Reaction 3Pharmacogenomic Testing 3Melphalan 3Everolimus 3Etoposide 3Dexamethasone 3ublituximab 2nelarabine 2ibritumomab tiuxetan 2fludarabine 2carfilzomib 2alvocidib 2Tacrolimus 2Methotrexate 2Magnetic Resonance Spectroscopy 2MLN 8237 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Waldenstrom Macroglobulinemia × pirtobrutinib × Clear all
NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Eli Lilly and Company

Phase 1 Active not recruiting
316 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡